摘要
Abstract
Objective:To analyze the effects of Paclitaxel combined with Carboplatin synchronous radiotherapy on tumor markers in elderly patients with non-small cell lung cancer(NSCLC).Method:Seventy elderly NSCLC patients admitted to Sichuan Provincial People's Hospital from January 2021 to January 2024 were selected and divided into an observation group(n=35,treated with Paclitaxel combined with Carboplatin synchronous radiotherapy)and a control group(n=35,treated with Paclitaxel combined with Cisplatin synchronous radiotherapy)according to the random lottery method.The clinical outcomes of the two groups were compared.Result:The total effective rate of the observation group was 94.29%,which was higher than 77.14%of the control group,the incidence of leukopenia(2.86%),nausea and vomiting(11.43%),alopecia(14.29%),thrombocytopenia(2.86%),and muscle and joint pain(2.86%)in the observation group were lower than those in the control group(20.00%,34.29%,37.14%,20.00%,22.86%),the differences were statistically significant(P<0.05).There were no significant differences in the levels of cytokeratin 19 fragment antigen(Cyfra 21-1),carcinoembryonic antigen(CEA),and squamous cell carcinoma antigen(SCC-Ag)between the two groups before treatment(P>0.05),after treatment,the Cyfra 21-1 of the observation group was(20.01±1.76)μg/L,CEA was(18.25±2.18)ng/mL,and SCC-Ag was(8.51±2.30)ng/L,which were lower than(25.94±2.10)μg/L,(22.23±2.24)ng/mL,and(10.34±2.26)ng/L of the control group,the differences were statistically significant(P<0.05).Conclusion:In the clinical treatment of elderly NSCLC patients,the use of Paclitaxel combined with Carboplatin synchronous radiotherapy has a relatively definite effect,with guaranteed effectiveness and safety,and can reduce tumor marker levels.关键词
紫杉醇/卡铂/同步放疗/非小细胞肺癌/肿瘤标志物Key words
Paclitaxel/Carboplatin/Synchronous radiotherapy/Non-small cell lung cancer/Tumor markers
